Want to see JNJ full AI Analyst Report?

Johnson & Johnson (JNJ) Stock Forecast & Price Target

28,361 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JNJ Analyst Ratings

Strong Buy

14 Buy

4 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Johnson

& Johnson

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JNJ Stock 12 Month Forecast

Average Price Target

$281.00

▲(6.68% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $281.00 with a high forecast of $305.00 and a low forecast of $255.00. The average price target represents a 6.68% change from the last price of $263.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"163":"$163","306":"$306","198.75":"$198.8","234.5":"$234.5","270.25":"$270.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$305.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":281,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$281.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$255.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[163,198.75,234.5,270.25,306],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.35,260.0923076923077,263.8346153846154,267.5769230769231,271.3192307692308,275.0615384615385,278.80384615384617,282.54615384615386,286.28846153846155,290.03076923076924,293.7730769230769,297.5153846153846,301.2576923076923,{"y":305,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.35,258.24615384615385,260.1423076923077,262.03846153846155,263.9346153846154,265.83076923076925,267.7269230769231,269.62307692307695,271.5192307692308,273.4153846153846,275.3115384615385,277.2076923076923,279.1038461538462,{"y":281,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,256.35,256.24615384615385,256.1423076923077,256.03846153846155,255.9346153846154,255.83076923076925,255.7269230769231,255.62307692307692,255.51923076923077,255.41538461538462,255.31153846153848,255.2076923076923,255.10384615384615,{"y":255,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":164.189,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.121,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.898,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.685,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.254,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.855,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.529,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.56,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.51,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.98,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$305.00

Average Price Target$281.00

Lowest Price Target$255.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Louise Chen

Scotiabank

$305

Buy

15.79%

Upside

Reiterated

08/04/26

Scotiabank Keeps Their Buy Rating on Johnson & Johnson (JNJ)

Terence Flynn

Morgan Stanley

$294

Buy

11.62%

Upside

Reiterated

08/03/26

Ottava Robotic Platform and MedTech Upside Underscore Buy Rating on JNJ with Unchanged $294 Price Target

Asad Haider

Goldman Sachs

$282

Buy

7.06%

Upside

Reiterated

08/03/26

JNJ’s OTTAVA Robotics and Medtech Strategy Underpin Buy Rating and Unchanged $282 Price Target

Larry Biegelsen

Wells Fargo

$272→$282

Buy

7.06%

Upside

Reiterated

08/03/26

Johnson & Johnson price target raised to $282 from $272 at Wells FargoJohnson & Johnson price target raised to $282 from $272 at Wells Fargo

Jason Gerberry

Bank of America Securities

$263

Hold

-0.15%

Downside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Nurix Therapeutics (NASDAQ: NRIX) and Johnson & Johnson (NYSE: JNJ)

David Toung

Argus Research

$290→$300

Buy

13.90%

Upside

Assigned

07/28/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Medios AG (Other OTC: MEDOF) and NeuroPace (NASDAQ: NPCE)

Vamil Divan

Guggenheim

$270

Buy

2.51%

Upside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH), Johnson & Johnson (NYSE: JNJ) and Thermo Fisher (NYSE: TMO)

Joanne Wuensch

Citi

$285→$298

Buy

13.14%

Upside

Reiterated

07/22/26

Citi Sticks to Its Buy Rating for Johnson & Johnson (JNJ)

Trung Huynh

RBC Capital

$287

Buy

8.96%

Upside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)

David Risinger

Leerink Partners

$265→$276

Buy

4.78%

Upside

Reiterated

07/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)

Jayson Bedford

Raymond James

$258→$265

Buy

0.61%

Upside

Reiterated

07/16/26

Johnson & Johnson price target raised to $265 from $258 at Raymond JamesJohnson & Johnson price target raised to $265 from $258 at Raymond James

Chris Schott

J.P. Morgan

$260→$270

Hold

2.51%

Upside

Assigned

07/16/26

Johnson & Johnson price target raised to $270 from $260 at JPMorganJohnson & Johnson price target raised to $270 from $260 at JPMorgan

Ilya Zubkov

Freedom Capital Markets

$280

Buy

6.30%

Upside

Upgraded

07/16/26

Johnson & Johnson upgraded to Buy from Hold at Freedom BrokerJohnson & Johnson upgraded to Buy from Hold at Freedom Broker

Rick Wise

Stifel Nicolaus

$260

Hold

-1.29%

Downside

Reiterated

07/15/26

JNJ: Strong Innovative Medicine Drives Guidance Raise but Mixed MedTech Keeps Risk/Reward Balanced, Supporting Hold Rating

Steve Scala

TD Cowen

$250→$300

Buy

13.90%

Upside

Reiterated

07/13/26

Johnson & Johnson price target raised to $300 from $250 at TD CowenJohnson & Johnson price target raised to $300 from $250 at TD Cowen

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Louise Chen

Scotiabank

$305

Buy

15.79%

Upside

Reiterated

08/04/26

Scotiabank Keeps Their Buy Rating on Johnson & Johnson (JNJ)

Terence Flynn

Morgan Stanley

$294

Buy

11.62%

Upside

Reiterated

08/03/26

Ottava Robotic Platform and MedTech Upside Underscore Buy Rating on JNJ with Unchanged $294 Price Target

Asad Haider

Goldman Sachs

$282

Buy

7.06%

Upside

Reiterated

08/03/26

JNJ’s OTTAVA Robotics and Medtech Strategy Underpin Buy Rating and Unchanged $282 Price Target

Larry Biegelsen

Wells Fargo

$272→$282

Buy

7.06%

Upside

Reiterated

08/03/26

Johnson & Johnson price target raised to $282 from $272 at Wells FargoJohnson & Johnson price target raised to $282 from $272 at Wells Fargo

Jason Gerberry

Bank of America Securities

$263

Hold

-0.15%

Downside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Nurix Therapeutics (NASDAQ: NRIX) and Johnson & Johnson (NYSE: JNJ)

David Toung

Argus Research

$290→$300

Buy

13.90%

Upside

Assigned

07/28/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Medios AG (Other OTC: MEDOF) and NeuroPace (NASDAQ: NPCE)

Vamil Divan

Guggenheim

$270

Buy

2.51%

Upside

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Molina Healthcare (NYSE: MOH), Johnson & Johnson (NYSE: JNJ) and Thermo Fisher (NYSE: TMO)

Joanne Wuensch

Citi

$285→$298

Buy

13.14%

Upside

Reiterated

07/22/26

Citi Sticks to Its Buy Rating for Johnson & Johnson (JNJ)

Trung Huynh

RBC Capital

$287

Buy

8.96%

Upside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)

David Risinger

Leerink Partners

$265→$276

Buy

4.78%

Upside

Reiterated

07/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)

Jayson Bedford

Raymond James

$258→$265

Buy

0.61%

Upside

Reiterated

07/16/26

Johnson & Johnson price target raised to $265 from $258 at Raymond JamesJohnson & Johnson price target raised to $265 from $258 at Raymond James

Chris Schott

J.P. Morgan

$260→$270

Hold

2.51%

Upside

Assigned

07/16/26

Johnson & Johnson price target raised to $270 from $260 at JPMorganJohnson & Johnson price target raised to $270 from $260 at JPMorgan

Ilya Zubkov

Freedom Capital Markets

$280

Buy

6.30%

Upside

Upgraded

07/16/26

Johnson & Johnson upgraded to Buy from Hold at Freedom BrokerJohnson & Johnson upgraded to Buy from Hold at Freedom Broker

Rick Wise

Stifel Nicolaus

$260

Hold

-1.29%

Downside

Reiterated

07/15/26

JNJ: Strong Innovative Medicine Drives Guidance Raise but Mixed MedTech Keeps Risk/Reward Balanced, Supporting Hold Rating

Steve Scala

TD Cowen

$250→$300

Buy

13.90%

Upside

Reiterated

07/13/26

Johnson & Johnson price target raised to $300 from $250 at TD CowenJohnson & Johnson price target raised to $300 from $250 at TD Cowen

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Johnson & Johnson

3 Months

Danielle AntalffyUBS

Success Rate

23/27 ratings generated profit

Average Return

+4.81%

Copying Danielle Antalffy's trades and holding each position for 3 Months would result in 85.19% of your transactions generating a profit, with an average return of +4.81% per trade.

1 Year

Danielle AntalffyUBS

Success Rate

27/27 ratings generated profit

Average Return

+14.08%

Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +14.08% per trade.

2 Years

Vamil DivanGuggenheim

Success Rate

18/19 ratings generated profit

Average Return

+20.45%

Copying Vamil Divan's trades and holding each position for 2 Years would result in 94.74% of your transactions generating a profit, with an average return of +20.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JNJ Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JNJ has received 36 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. JNJ average Analyst price target in the past 3 months is 281.00.

Each month's total comprises the sum of three months' worth of ratings.

JNJ Financial Forecast

JNJ Earnings Forecast

Next quarter’s earnings estimate for JNJ is $2.94 with a range of $2.31 to $3.18. The previous quarter’s EPS was $2.90. JNJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Sales Forecast

Next quarter’s sales forecast for JNJ is $25.32B with a range of $25.04B to $25.55B. The previous quarter’s sales results were $25.32B. JNJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Stock Forecast FAQ

What is JNJ’s average 12-month price target, according to analysts?

Based on analyst ratings, Johnson & Johnson’s 12-month average price target is 281.00.

What is JNJ’s upside potential, based on the analysts’ average price target?

Johnson & Johnson has 6.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JNJ a Buy, Sell or Hold?

Johnson & Johnson has a consensus rating of Strong Buy which is based on 14 buy ratings, 4 hold ratings and 0 sell ratings.

What is Johnson & Johnson’s price target?

The average price target for Johnson & Johnson is 281.00. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $305.00 ,the lowest forecast is $255.00. The average price target represents 6.68% Increase from the current price of $263.4.

What do analysts say about Johnson & Johnson?

Johnson & Johnson’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of JNJ?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Johnson & Johnson (JNJ) Stock Forecast & Price Target

JNJ Analyst Ratings

JNJ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Johnson & Johnson

JNJ Analyst Recommendation Trends

JNJ Financial Forecast

JNJ Earnings Forecast

JNJ Sales Forecast

JNJ Stock Forecast FAQ

Detailed List of Analyst Forecasts